title: [Effect of hypotensive therapy on metalloproteinase activity of the blood in patients with arterial hypertension].
abstract: Aim of the study--investigation of dynamics of levels of serum markers of myocardial fibrosis matrix metalloproteinase-1 (MMP-1), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1)--at the background of 3 months hypotensive therapy in 39 patients with arterial hypertension and paroxysmal form of atrial fibrillation. Twenty patients received sotalol, 19--retard form of verapamil. After 3 months of hypotensive therapy in all patients and separately in groups of patients receiving sotalol and verapamil no significant changes of MMP-1 and TIMP-1 occurred. However in patients with most pronounced hypotensive effect according to 24-hour blood pressure monitoring significant elevation of MMP-1 and lowering of TIMP-1 levels took place. This was associated with improvement of ventricular diastolic function. In most patients longer period of therapy (more than 3 months) is required for achievement of regression of damage to the heart.
authors.forename: N A
authors.initials: NA
authors.lastname: Mazur
authors.forename: F M
authors.initials: FM
authors.lastname: Khezheva
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D018660:Blood Pressure Monitoring, Ambulatory; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005355:Fibrosis / Q000201:enzymology / Q000209:etiology / Q000473:pathology; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000201:enzymology / Q000209:etiology / Q000473:pathology; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000201:enzymology*; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000097:blood* / Q000187:drug effects; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D013015:Sotalol / Q000627:therapeutic use; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood* / Q000187:drug effects; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014700:Verapamil / Q000627:therapeutic use*
chemical_list: D000319:Adrenergic beta-Antagonists; D019715:Tissue Inhibitor of Metalloproteinase-1; D014665:Vasodilator Agents; D013015:Sotalol; D014700:Verapamil; D020781:Matrix Metalloproteinase 1